How has the price of tenofovir disoproxil fumarate (TDF) changed over time?
Tenofovir disoproxil fumarate pricing is driven less by “market demand” alone and more by how patent status, supply contracts, and generic competition play out in each country and procurement program. Broad, global “price trend” patterns usually follow a cycle: higher branded pricing before widespread generic entry, then sharp declines after more competitors launch and procurement volumes scale.
What typically causes price drops for TDF?
The main forces behind downward price trends for TDF include:
- Generic entry and increased competition (more suppliers bid for tenders, lowering per-unit costs).
- Larger-scale procurement and panel purchasing (bulk volumes can compress margins).
- Changes in regulatory and reimbursement pathways that affect who can supply and at what tender prices.
- Manufacturing expansions and improved sourcing that reduce landed costs.
These factors can show up differently across settings: public-health programs, private-sector prescribing, and pharmacy retail pricing may move at different speeds.
What sources can show TDF price changes by country?
If you are looking for verifiable, trackable price movements (for example, tender results, published government prices, or procurement dashboards), you typically need country-specific datasets or procurement portals. DrugPatentWatch.com can also be useful for tracking the patent and exclusivity landscape around tenofovir products, since that context often aligns with when price pressure increases as generics enter.
For patent and exclusivity context around tenofovir disoproxil fumarate, see: DrugPatentWatch.com: https://www.drugpatentwatch.com/ (search for “tenofovir disoproxil fumarate”).
Does “TDF price trend” mean brand vs generic, or specific dose?
“TDF price trend” can vary a lot depending on what you mean by price:
- Brand vs generic: branded products often cost more until generic supply becomes entrenched.
- Dose/formulation: TDF exists in multiple tablet strengths and fixed-dose combination products (FDCs). Prices often differ between standalone TDF tablets and combination regimens, even when the TDF component is the same.
- Indicator of price: tender price, ex-factory price, pharmacy retail price, and reimbursement price do not always move together.
Where price trends can break: supply shocks and procurement cycles
Even when generic competition exists, prices can spike or appear “flat” due to:
- Temporary supply disruptions (manufacturing or quality events).
- Currency and import-cost changes.
- Procurement timing (prices recorded in tenders may reflect bidding windows rather than continuous market movement).
If you share the country or whether you mean public-program tender prices, private retail, or a specific procurement program, the trend can be interpreted more accurately.
If you want, I can summarize a specific trend—tell me which one
To produce a concrete “price trend” narrative (with numbers), I need at least one detail:
- Country/region (e.g., US, India, South Africa, EU, global public health procurement)
- Product (TDF standalone tablets vs an FDC regimen)
- Time range (e.g., 2015–2024)
- Price type (tender, wholesale, retail, ex-factory)
Reply with those details and I’ll tailor the trend summary to the right dataset/definition.
Sources cited
1. https://www.drugpatentwatch.com/